Signs, Symptoms And Laboratory Findings Of Acute Overdosage In Humans

The signs and symptoms for KEPPRA XR (levetiracetam extended-release tablets) overdose are expected to be similar to those seen with immediate-release KEPPRA tablets.

The highest known dose of oral immediate-release KEPPRA received in the clinical development program was 6000 mg/day. Other than drowsiness, there were no adverse reactions in the few known cases of overdose in clinical trials. Cases of somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with immediate-release KEPPRA overdoses in postmarketing use.

Treatment Or Management Of Overdose

There is no specific antidote for overdose with KEPPRA XR (levetiracetam extended-release tablets) . If indicated, elimination of unabsorbed drug should be attempted by emesis or gastric lavage; usual precautions should be observed to maintain airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the patient's Center should be contacted for up to date information on the management of overdose with KEPPRA XR (levetiracetam extended-release tablets) .

Hemodialysis

Standard hemodialysis procedures result in significant clearance of levetiracetam (approximately 50% in 4 hours) and should be considered in cases of overdose. Although hemodialysis has not been performed in the few known cases of overdose, it may be indicated by the patient's clinical state or in patients with significant renal impairment.

None

Last reviewed on RxList: 3/13/2009
This monograph has been modified to include the generic and brand name in many instances.